Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity
Science Advances · 2026
DOI: 10.1126/sciadv.aeh9215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Mathias Vormehr und 10 weiteren Autor:innen. Beteiligte Einrichtung: BioNTech SE, Mainz, Germany. Hauptthemen laut MEDLINE: Interleukin-2, RNA, Messenger, Interleukin-2 Receptor alpha Subunit, Interleukin-2 Receptor beta Subunit. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BioNTech.
Abstract (Originalsprache)
The therapeutic potential of interleukin-2 (IL-2) in cancer treatment is limited by toxicity challenges, partly due to an unfavorable pharmacokinetic profile and unintended activation of regulatory T (T reg ) cells alongside the desired activation of CD8 + effector T cells. To selectively stimulate CD8 + T cells over T reg cells, we engineered an IL-2 variant (IL-2var) with a dual-tuned affinity profile that features reduced binding to IL-2Rα (CD25) and enhanced binding to IL-2Rβ (CD122). To optimize its pharmacokinetics and facilitate tumor enrichment, the variant is fused to albumin and delivered as an mRNA encapsulated in a lipid nanoparticle (Alb–IL-2var RNA-LNP), enabling sustained systemic exposure from hepatic production upon intravenous administration. We show that Alb–IL-2var has a favorable pharmacokinetic profile and is tolerated at biologically active doses in immunocompetent mice and cynomolgus monkeys. Selective enhancement of CD8 + T cell responses over T reg cells is demonstrated in vitro in human peripheral blood mononuclear cells and in vivo in mice and cynomolgus monkeys. When combined with an mRNA cancer vaccine in syngeneic subcutaneous mouse tumor models, Alb–IL-2var RNA-LNP stimulates the expansion of tumor-infiltrating and circulating tumor antigen–specific CD8 + T cells, but not T reg cells. In advanced and cold syngeneic tumor models, it enhances the efficacy of radiotherapy, checkpoint inhibitors, and cancer vaccines. Combination with checkpoint inhibitors and vaccine induces profound proinflammatory conversion of cold tumors. These preclinical results validate a rational design approach to overcome the limitations of IL-2 therapy and support the clinical evaluation of Alb–IL-2var RNA-LNP for solid cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- BioNTech SE, Mainz, Germany.
- TRON gGmbH - Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
- HI-TRON - Helmholtz Institute for Translational Oncology Mainz (HI-TRON Mainz) of the DKFZ, Mainz, Germany.
ORCID-Profile: Mathias Vormehr, Lena M Kranz, Alexander Muik, Sina Fellermeier-Kopf, Jan D Beck, Nadja Salomon, Bonny Gaby Lui, Ugur Sahin
Förderung
- BioNTech
Zitieren
APA
Vormehr, M., Kranz, L. M., Muik, A., Fellermeier-Kopf, S., Beck, J. D., Eisel, D., Salomon, N., Lui, B. G., Diekmann, J., Türeci, Ö., & Sahin, U. (2026). Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity. Science Advances. https://doi.org/10.1126/sciadv.aeh9215
Vancouver
Vormehr M, Kranz LM, Muik A, Fellermeier-Kopf S, Beck JD, Eisel D, et al. Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity. Science Advances. 2026. doi:10.1126/sciadv.aeh9215
BibTeX
@article{Vormehr2026,
author = {Vormehr, Mathias and Kranz, Lena M and Muik, Alexander and Fellermeier-Kopf, Sina and Beck, Jan D and Eisel, David and Salomon, Nadja and Lui, Bonny Gaby and Diekmann, Jan and Türeci, Özlem and Sahin, Ugur},
title = {Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeh9215}
}
EUVIMED